白细胞介素17A介导银屑病及心血管合并症的研究进展  

Interleukin-17A-mediated psoriasis and cardiovascular comorbidities

作　　者：赵莹 王娟娟 季江[1] 苏文星 魏钰倩 冷红[1] 丁瑜洁[1] 施辛[1] Zhao Ying;Wang Juanjuan;Ji Jiang;Su Wenxing;Wei Yuqian;Leng Hong;Ding Yujie;Shi Xin(Department of Dermatology and Venereology,The Second Affiliated Hospital of Soochow University,Suzhou 215004,China)

机构地区：[1]苏州大学附属第二医院皮肤性病科,苏州215004

出　　处：《中华皮肤科杂志》2022年第1期76-79,共4页Chinese Journal of Dermatology

基　　金：国家自然科学基金(81803127);苏州市民生科技项目(SS201643);苏州市科技发展计划项目(SYS2018056)。

摘　　要：白细胞介素(IL)-23/IL-17轴是寻常型斑块状银屑病发病的主要通路,IL-17A是相关免疫通路中的关键节点,介导了动脉粥样硬化和银屑病的重叠炎症通路,促进炎症、凝血和血栓形成,在银屑病心血管合并症的发生发展中起重要作用。抑制IL-17A的炎症作用能减少重度银屑病患者心血管合并症的发生率及病死率。本文综述近年来IL-17A介导银屑病的全身性炎症及其心血管合并症的研究进展,为临床上预防及减少银屑病患者心血管合并症提供参考。The interleukin(IL)-23/IL-17 axis is the main pathway in the pathogenesis of plaque-type psoriasis vulgaris,and IL-17A plays a key role in the relevant immune pathways.IL-17A mediates overlapping inflammatory pathways in atherosclerosis and psoriasis,promotes inflammation,coagulation and thrombosis,and plays an important role in the occurrence and development of cardiovascular comorbidities in patients with psoriasis.Inhibiting the inflammatory effect of IL-17A can reduce the incidence and mortality of cardiovascular comorbidities in patients with severe psoriasis.This review summarizes recent research progress in IL-17A-mediated systemic inflammation and cardiovascular comorbidities in patients with psoriasis,and provides a reference for prevention and reduction of cardiovascular comorbidities in patients with psoriasis in clinical practice.

关 键 词：银屑病 白细胞介素17 心血管疾病 共病现象 白细胞介素17A 

分 类 号：R758.63[医药卫生—皮肤病学与性病学] R54[医药卫生—临床医学]